https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...
acute myelocytic leukemiapharma grouplisaftoclaxinternational